Kidney/Hypertension Section, E P Joslin Research Laboratory, Joslin Diabetes Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Int J Mol Sci. 2023 Jun 2;24(11):9670. doi: 10.3390/ijms24119670.
A wide spectrum of Gram-positive/Gram-negative bacteria has been found resistant to a wide spectrum of antibiotics in the United States of America during the past decade. Drug-resistant tuberculosis is not yet a major threat in North/South America, Europe, and the Middle East. However, the migration of populations in times of drought, famine, and hostilities may increase the global reach of this ancient pathogen. Given an increased spread from China and India to African countries, drug-resistant has become an emerging topic of concern for Europe and North America. Due to the dangers associated with the spread of pathogens among different populations, the World Health Organization continues to expand healthcare advisories for therapeutic approaches for both stationary and migrating populations. As much of the literature focuses on endemic to pandemic viruses, we remain concerned that other treatable communicable diseases may be ignored. One such disease is multidrug-resistant tuberculosis. We focus on molecular mechanisms that this pathogen relies upon for the development of multidrug resistance via gene mutation and the evolutionary development of new enzyme and calcium channels.
在过去十年中，美国发现了广泛的革兰氏阳性/革兰氏阴性细菌对广泛的抗生素产生了耐药性。耐多药结核病在北美/南美、欧洲和中东尚未构成重大威胁。然而，在干旱、饥荒和敌对时期人口的迁移可能会增加这种古老病原体的全球传播范围。鉴于中国和印度向非洲国家的传播增加，耐药性已成为欧洲和北美的一个新出现的令人关注的问题。由于病原体在不同人群中传播所带来的危险，世界卫生组织继续扩大对固定和流动人群治疗方法的医疗保健建议。由于大部分文献都集中在地方性到大流行性病毒上，我们仍然担心其他可治疗的传染病可能会被忽视。其中一种疾病是耐多药结核病。我们专注于该病原体通过基因突变和新酶及钙通道的进化发展，从而产生耐多药的分子机制。
